RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

Blast-phase chronic myeloid leukemia (BP-CML) is associated with additional chromosomal aberrations, RUNX1 mutations being one of the most common. Tyrosine kinase inhibitor therapy has only limited efficacy in BP-CML, and characterization of more defined molecular subtypes is warranted in order to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Adnan Awad, Shady, Dufva, Olli, Ianevski, Aleksandr, Ghimire, Bishwa, Koski, Jan, Maliniemi, Pilvi, Thomson, Daniel, Schreiber, Andreas, Heckman, Caroline A., Koskenvesa, Perttu, Korhonen, Matti, Porkka, Kimmo, Branford, Susan, Aittokallio, Tero, Kankainen, Matti, Mustjoki, Satu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024199/
https://www.ncbi.nlm.nih.gov/pubmed/32782381
http://dx.doi.org/10.1038/s41375-020-01011-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024199/
https://www.ncbi.nlm.nih.gov/pubmed/32782381
http://dx.doi.org/10.1038/s41375-020-01011-5

Ejemplares similares